Skip to main content
MIRA PHARMACEUTICALS, INC. logo

MIRA PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · MIRA ISIN · US60458C1045 LEI · 5493000N6HPDY7V7OR15 US Manufacturing
Filings indexed 173 across all filing types
Latest filing 2026-03-31 Annual Report
Country US United States of America
Listing US MIRA

About MIRA PHARMACEUTICALS, INC.

https://mirapharmaceuticals.com/

MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical development company focused on therapies for neurologic and neuropsychiatric disorders. The company's pipeline features two primary neuroscience programs. The first is Ketamir-2, an oral ketamine analog being developed for the treatment of pain and depression. The second is MIRA-55, a synthetic marijuana analog targeting anxiety and cognitive decline. MIRA aims to develop next-generation therapeutics that are safer, more accessible, and affordable for patients.

Recent filings

Filing Released Lang Actions
10-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
Annual Report FY 2025
2026-03-31 English
8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
Regulatory Filings
2026-03-23 English
8-K - MIRA PHARMACEUTICALS, INC. (0001904286) (Filer)
Regulatory Filings
2026-03-03 English
5 Filing
Director's Dealing
2026-02-17 English
8-K Filing
Regulatory Filings
2026-02-02 English
8-K
Regulatory Filings
2025-12-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.